ClinicalTrials.gg
Active, not recruitingNCT06495229Updated Oct 2, 2025

Study of CM310 in Adolescent Subjects With Atopic Dermatis

A Phase 3 interventional study of CM310 in Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Active, not recruiting at 1 site in China. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Keymed Biosciences Co.Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing stapokibart in Dermatitis, Atopic — 2 open to participants now, 3 under way, 3 of them phase 3. stapokibart · Dermatitis, Atopic.

Planned enrollment
5th of 12
180 · median 170
Started
2024
with 1 other
Phase 3
5 of 12
2 open now
Registered
10th of 12
by date
Lead sponsor
12 of 12
Keymed Biosciences Co.Ltd

Among the 12 studies testing stapokibart in Dermatitis, Atopic, this one is the 5th largest by planned enrollment, is one of 2 that started in 2024, is one of 5 in phase 3, and was the 10th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 12 studies testing stapokibart in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About stapokibart

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing stapokibart in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a multi-center, single arm, open label phase 3 study to evaluate the safety and efficacy of CM310 in children patients with moderate-to-severe atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have the ability to understand the study and voluntarily sign a written form (ICF).
  • Subjects who must complete the evaluation of Week 18 of the main study.
  • With Atopic Dermatitis.

Exclusion criteria

Exclusion Criteria:

  • Any major surgery planned during the research period.
  • Subjects with potential fertility do not agree to adopt efficient measures throughout the entire study period; Pregnant or breastfeeding women, or women planning to conceive or breastfeed during the study period.
  • With any circumstance that the subject is not suitable to participate in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    CM310 group

    Biological: CM310

Interventions

  • BiologicalCM310

    Interleukin-4 receptor(IL-4Rα) monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Adverse events

    Incidence of adverse events.

    Time frame: up to week 52

Secondary outcomes

  1. Change from baseline in Eczema Area and Severity Index (EASI)

    Changes from baseline in Eczema Area and Severity Index (EASI)

    Time frame: up to week 62

  2. Proportion of subjects with Immunoglobulin A(IGA) 0 or 1 and a reduction of from baseline of ≥ 2 points

    Proportion of subjects with IGA 0 or 1 (on a 5-point scale, range from 0-4 point, higher scores mean a worse disease severity) and reduction ≥2 points from baseline.

    Time frame: up to week 62

  3. Improvement of Numerical Rating Scale (NRS)

    Proportion of subjects with improvement (reduction) of pruritus NRS from baseline. The range of NRS is from 0 (no itch)-10 (worst imaginable itch).

    Time frame: up to week 62

  4. Body surface area (BSA) of involvement of atopic dermatitis

    Change from baseline in percent of BSA

    Time frame: up to week 62

  5. Children Dermatology Life Quality Index (CDLQI)

    Changes from baseline in CDLQI

    Time frame: up to week 62

  6. Patient-Oriented Eczema Measure (POEM)

    Changes from baseline in POEM

    Time frame: up to week 62

  7. EuroQol Five Dimensions Questionnaire (EQ-5D)

    Changes from baseline in EQ-5D

    Time frame: up to week 62

  8. Pharmacokinetics parameters

    Trough concentration and exposure of CM310

    Time frame: up to week 62

  9. Immunogenicity

    Detection of anti-drug antibody (ADA) and neutralizing antibody (Nab)

    Time frame: up to week 62

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2026, 24 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 24 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 10, 2024
StartActual
Aug 2, 2024
Primary completionEst.
Aug 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06495229
Responsible party
Sponsor
First posted
Jul 10, 2024
Start date
Aug 2, 2024
Primary completion
Aug 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Oct 2, 2025

Study contacts

jianzhong Zhang
principal investigator · Peking University People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion